The gastric cancer drug market is set to experience rapid expansion over the next 10 years.
By Dustin Phan, Analyst
8 April 2016
I am an analyst at Datamonitor Healthcare based in the San Diego – California office, where I am currently a member of...
Read full bio
Datamonitor Healthcare forecasts that the gastric cancer market will experience a rapid increase in drug sales from 2015-2024.
Datamonitor Healthcare surveyed 227 gastroenterologists and medical oncologists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain insight into current and future prescribing trends in advanced and metastatic gastric cancer. The primary drivers for this rapid growth include increasing incidence of gastric cancer in all markets, combined with the approval and subsequent uptake of next-generation targeted therapies and immunotherapies. Sales of key therapies in this indication are expected to grow from $240m in 2015 to $2,288m in 2024.
In particular, the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor class of drugs is expected to be the best-selling class by 2024, with sales estimated to reach $1,275m. Pipeline PD-1/PD-L1 inhibitors include Keytruda (pembrolizumab; Merck & Co), avelumab (Merck KGaA/Pfizer), and Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical). In particular, Keytruda is expected to reach sales of over $900m by 2024. This growth will be driven by potential approvals in the first- and second-line treatment settings.
Gastric cancer market sales across the US, Japan, and five major EU markets, by country, 2015-2024
Source: Datamonitor Healthcare
This ResearchWire is based on Datamonitor Healthcare’s Gastric Cancer: Forecast – which covers the expected impact of newly branded therapies on the gastric cancer market, as well as a detailed look at the current gastric cancer pipeline.
Get your free demo today – simply fill out the form to the right.